FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy’s Disease

TAIPEI, Oct. 23, 2025 /PRNewswire/ — AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and bulbar muscular atrophy (SBMA, also known as…